• Explore /
  • Poster
  • / VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for <em>BRAF</em> <em>V600E</em>-mutated advanced colorectal cancer.

VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.

Abstract Poster

Authors

null

Yijiao Chen

Colorectal Cancer Center; Department of General Surgery; Zhongshan Hospital, Fudan University, Shanghai, China, Shanghai, China

Yijiao Chen , Dexiang Zhu , Ye Wei , Jianmin Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT05540951

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3596)

DOI

10.1200/JCO.2023.41.16_suppl.3596

Abstract #

3596

Poster Bd #

296

Abstract Disclosures

Similar Posters

First Author: Ying Liu

First Author: Sebastian Stintzing

First Author: Arthur C. Houts

First Author: Howard S. Hochster